Rockwell Medical Technologies (NASDAQ: RMTI) reported Q4 EPS of ($0.17), versus ($0.18) reported last year. Revenue for the quarter came in at $16.9 million, versus $14.8 million reported last year.

Key Objectives for 2019

• Launch Dialysate Triferic in the U.S. in the second quarter of 2019;
• File an NDA with the FDA for I.V. Triferic in the second quarter of 2019;
• Accelerate global development of Triferic through existing partners and identify new partners for key geographies, including Europe and Japan; and
• Grow and improve the profitability of the Company’s concentrates business.

For earnings history and earnings-related data on Rockwell Medical Technologies (RMTI) click here.